Sign in Subscribe
Universities and colleges

Cathepsin E Enhances Anticancer Activity of Doxorubicin on Human Prostate Cancer Cells Resistant to TRAIL-Mediated Apoptosis

Strategic Insights

— 1 min read

Recent research from Fukuoka, Japan, led by A. Yasukochi and colleagues at Kyushu University, has shed light on a promising therapeutic approach for prostate cancer. The study, published in Biological Chemistry, demonstrates that combining cathepsin E with doxorubicin can overcome resistance to apoptosis in human prostate cancer cells, thereby enhancing the efficacy of the anticancer treatment.

Key Takeaways:

  • The study found that cathepsin E can induce growth arrest and apoptosis in human prostate cancer cell lines in vitro, including PPC-1 cells, which are relatively resistant to cell death by doxorubicin.
  • Combination treatment with cathepsin E and doxorubicin synergistically induces viability loss in PPC-1 cells, mainly due to down-regulation of the short form of the FLICE inhibitory protein FLIP.
  • In vivo studies with athymic mice bearing PPC-1 xenografts showed that intratumoral application of cathepsin E in doxorubicin-treated mice results in tumor cell apoptosis and tumor regression.
  • The enhanced antitumor activity was attributed to enhanced TRAIL-induced apoptosis through doxorubicin-induced c-FLIP down-regulation and a decrease in tumor cell proliferation.
  • The study suggests that the combination of cathepsin E and doxorubicin may have therapeutic potential for clinical use in overcoming resistance to apoptosis in chemoresistant prostate cancer cells.

Statistics:

  • 40-50% cytotoxicity of doxorubicin in PPC-1 cells, indicating resistance to cell death by this agent.
  • 947-58, the pages of the Biological Chemistry journal where the study was published.
  • 13, the street number of the publisher Wolters Kluwer of the journal Biological Chemistry (although this was repeated as Genthiner Strasse 13).
  • D-10785, the postal code of Berlin, Germany, where the publisher Wolters Kluwer is located.

Sources:

  • A. Yasukochi et al., "Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis," Biological Chemistry, vol. 391, no. 8 (2010), pp. 947–958.
  • Kyushu University, "Contact: A. Yasukochi, Department of, Kyushu University, Fukuoka, Japan."

Read more